Cel Sci Corporation New (CVM) 銘柄情報

CVM, new 52 week low

CVM, new 52 week low

Unfortunately it looks like the RS will become a reality by the end of the week. One for ten seems about right for a $3 stock price post split. With some preliminary news of the confirmatory trials due sometime in the Summer, this stock may be bought for $1.50- 2.50 in a few months. Not a bad spec for those who still believe in the technology.

And still a lot of nothing,...

Whatever happened to rdneum? He's a one stock poster. One and done. So much for his wisdom. Another loser like myself.

$823.84 to be EXACT !

I wonder how this one stays on the AMEX with it's share price this low? All I know is I lost $800 from this scam.

They did a toxic spiral finance deal some years back that they can't shed.

The way I read it there virtually guaranteed the extension if they want it since they have a product that has a good chance of final phase III approval within a year or so. Also, SEC looks at past stock price manipulation practices (i.e. several reverse splits in a short period of time to maintain price compliance along with other shady practices) of which CVM arguably doesn't have. One reverse split back in 2017 is the only one I'm aware of. All good news for CVM. With that being said, I'm very high on CVM since all it will take is one or two favorable results article from the regulatory study which imo will happen somewhere around June or July maybe Aug to get the stock price back over $1.00. Plus that is about the time they will need more funding from a public offering to carry them through the rest of the year. also sounds like the treatment shows it's effectiveness results in roughly 3 weeks after treatment start. Something will leak out just in time for everything to come to gather. before October.

Unfortunately there has been significant reverse split activity in this stock. We will ee in March if there is an "automatic" extension of an additional 180 days before delisting threat gives rise to a reverse split again.

The new of some nice confirmatory results did provide a one day boost to high 60s before it fell back.

You won't hear anything for awhile since the reverse split option isn't really on the table until roughly October 2025. Nasdaq rules state the companies who don't regain share price compliance within 180 days from notification are automatically give a second 180 days to regain listing compliance (for a total of 360 days). (see: Listing Rule 5815(a)(1)(B)(ii)d ) Since the last time CVM closed above 1.00 was around October 11, 2024 they got until October 2025 to get there. With the regulatory study proceeding and no significate reverse split activity in CVM's past, there's no reason for Nasdaq/SEC to not grant the second 180 days. The only thing to look out for are public offerings which CVM has done roughly two to three times per year for the past few years.

I've seen you on several boards recently. Seems you're working hard to pump RNAZ. A company that recently has been HEAVILY shorted. Is losing a ton of money and from what I can, is known mostly for reverse splits ( 3 in a year and a half).
What is your purpose again?

cvm,,,,,,,,,,,,,,,,,,https://stockcharts.com/h-sc/ui?s=CVM&p=W&b=5&g=0&id=p86431144783

CVM: Fiscal Year 2024 Results
02/10/2025
By John Vandermosten, CFA

NYSE:CVM

READ THE FULL CVM RESEARCH REPORT

CEL-SCI Corporation (NYSE:CVM) reports fiscal year 2024 financial and operational results. The press release and Form 10-K filing encapsulate a year of preparation for confirmatory registration studies around the globe. CEL-SCI cleared its proposed 212-patient registration study of Multikine with the FDA. This narrowed the population to patients with squamous cell carcinoma of the head and neck (SCCHN) with no lymph node involvement and low PD-L1 tumor expression. A contract research organization (CRO) was selected to run the trial and data was presented from the IT-MATTERS study showing 73% survival for Multikine vs. 45% in the control arm at five years. Outside of the US, the European Medicines Agency (EMA) Pediatric Committee and the United Kingdom’s Healthcare Products Regulatory Agency (MHRA) granted Multikine a pediatric waiver, streamlining the process for obtaining approval in these jurisdictions.

Financial Review

CEL-SCI recognized no revenues for its fiscal year ending September 30, 2024. It consumed $26.4 million in operational expenses generating a net loss of ($27.6) million or ($0.51) per share.

For the year ending September 30, 2024 versus the same prior year period:

Expenses for research and development fell 19% to $18.2 million from $22.5 million. Lower Phase III study, employee stock compensation and miscellaneous costs contributed to the decrease and were partially offset by increases in other research and development costs;
General and administrative expenses decreased 9% to $8.2 million from $9.0 million on lower employee stock compensation and other miscellaneous expenses;
Other non-operating items were $177,000 compared to ($43,000) in the prior year;
Net interest expense was relatively constant at ($0.7) million related to interest income from cash balances and expense from finance leases;
Derivative modifications totaled ($659,000) compared to ($172,000);
Net loss totaled ($27.6) million versus ($32.4) million or ($0.51) and ($0.73) per share, respectively.
As of September 30, 2024, cash and equivalents totaled $4.7 million. Cash burn for the twelve-month period amounted to approximately ($18.9) million, up from 2023’s ($23.2) million. Following the end of the fiscal year, CEL-SCI closed on a gross $5 million stock offering. CEL-SCI holds no debt on its balance sheet. The company estimates that the confirmatory trial will cost $30 million.

FDA Confirmatory Study Acceptance

Last May, CEL-SCI announced that its selection criteria for populating a confirmatory study and study design was cleared by the FDA. In a subsequent meeting, the agency indicated that the company may move forward with a confirmatory registration study of Multikine to evaluate its safety and efficacy in squamous cell head and neck cancer (SCCHN). Acceptable patients will be newly diagnosed with advanced primary SCCHN with no lymph node involvement (determined via PET scan) and with low PD-L1 tumor expression (determined via biopsy). Statistical analysis indicates that 212 subjects will be required to generate the confirmatory data. In November 2024, the FDA and CEL-SCI agreed upon the use of the PD-L1 biomarker to select patients for the trial.

Based on a discussion of the path forward with the FDA which was included in a 29 page report, the agency responded in written notes accepting the eligibility criteria. It further acknowledged that the nonclinical data appears to be sufficient, the stratification factors appear reasonable and CEL-SCI’s approach for product specifications is acceptable. Furthermore, the FDA had no safety objections to further treatment of patients with Multikine.

Similar to the IT-MATTERS study, we anticipate that eligible individuals will have a diagnosis of untreated SCCHN, measurable tumor, normal immune function and no use of immunosuppressives in the previous year among other criteria. Based on the performance in the Phase III trial, further population characteristics for the confirmatory study will include patients with no lymph node involvement of the disease and low PD-L1 tumor expression.



The study design calls for a two arm, two stage, 1:1 randomized controlled trial enrolling 212 subjects. The first stage will examine pre-surgical response rates, which can be determined shortly after completion of enrollment. Stage two will assess overall survival (OS) as the primary endpoint. Histopathology biomarkers will also be measured.



In its confirmatory trial, CEL-SCI anticipates that it will need to surpass a hurdle of a 10% improvement in overall survival (OS) and produce a hazard ratio of 0.72 or less to merit approval. In the IT-MATTERS study, the target population achieved a 28.5% improvement in OS and produced a hazard ratio of 0.35.

In a December 12th press release, CEL-SCI explained the biologic rationale for the use of Multikine in the confirmatory registrational head and neck cancer study. The discussion referred to the results from the IT-MATTERS study and emphasized the significant rates of tumor regression before surgery in both the Phase II and Phase III studies and the 73% survival with Multikine vs. a 45% for the control patients not treated with Multikine. Other supporting points include:

Benefit to the patient prior to surgery and when the immune system remains strong;
Statistical significance of p=0.0015 and hazard ratio of 0.35 in 114 patients for overall survival (OS);
Eligible patients have no lymph node involvement and low PD-L1 tumor expression;
No excess toxicity beyond the standard of care.
Links to Previous Reports and Background on Multikine

Summary of ESMO Poster Presentation – discussion of lymph node spread and PD-L1 expression
Review of IT-MATTERS population analysis & overall survival comparison
FDA ODAC Opinion
CEL-SCI Milestones

Giovanni Selvaggi joins CEL-SCI as clinical advisor – June 2024
Presentation at the International Drug Discovery Science & Technology (IDDST) Congress – June 2024
CEL-SCI appoints Robert Watson as Chairperson of the Board – July 2024
Feedback from various regulatory agencies - 2024
Submission of license application to various agencies – 2024+
Grant of pediatric waiver by UK’s MHRA – September 2024
ESMO poster presentation provides new data – September 2024
UK’s MHRA grants pediatric waiver to Multikine – September 2024
Ergomed selected as CRO for confirmatory trial – October 2024
FDA ODAC opines against use of checkpoints in low PD-L1 expression patients – Fall 2024
FDA agrees to use of PD-L1 biomarker in Multikine registration study – November 2024
Full enrollment of confirmatory trial – 2Q:26
Clinical Research Organization (CRO) Selection

CEL-SCI selected Ergomed to serve as its CRO for the upcoming confirmatory registration study of Multikine. Details of the selection were included in an October 1st press release. Ergomed had previously provided CRO services to CEL-SCI for the management of the IT-MATTERS trial. Ergomed will manage the trial globally at multiple sites. The announcement reminded readers that the trial will be a 212-patient study enrolling newly-diagnosed, locally advanced, primary head and neck cancer. It will focus on patients with no lymph node involvement and low PD-L1 tumor expression. The anticipated start of the confirmatory trial is 1Q:25.

Capital Raise

CEL-SCI announced the closing of its $5 million offering on December 31st in a press release. The company sold 16,130,000 shares of stock and pre-funded warrants at $0.31 per share. ThinkEquity served as the placement agent for the transaction.

Summary

CEL-SCI is completing the necessary prerequisites for launching its registrational trial in the United States. The trial design has been completed with plans to enroll 212 subjects that conform to specific biomarkers. The trial will include low-risk patients that are appropriate for radiotherapy but not chemotherapy and with low PD-L1 expression. CEL-SCI has also selected its CRO, Ergomed, which also provided these services for the IT-MATTERS trial. Other positive news for immunotherapies are the opinions shared at the November ODAC meeting. At that meeting, a majority of experts asserted that on the whole checkpoint inhibitors could be harmful for patients with low PD-L1 expression, providing support for alternatives such as Multikine if it is approved.

At new 52 week low, it appears to be telegraphing the reverse split in 5 weeks. The confirmatory trial would have to be announced soon and be spectacular to avoid it. Sorry

That's awesome FD ! Ah speaking of Indian Reservations reminded me.... My father LIVED on their reservations for quite some time and no WHITE man is allowed to do so. Reason being is because my father befriended them and gained their trust. And he lived on there because he had no money to live normally. My father ate out of dumpsters for a time. He would take the discarded old food from restaurants. Must have shamed him to no end to do that. Probably because my father would not take a dime from government handouts.
Oh and that 13 day hell for me was not just in Arizona but across the whole Continental United States. I live in New York and I drove home in a UHAUL with his items. Took me 5 days that should have taken me only 3 at most.

P.S. My father used to come home to New York from Tucson Arizona and make it in only 36 hours. No sleeping and cruising average speed of 110 miles per hour in his '64 Buick. State Trooper once tried to catch him and he had to pull over and wait for the Trooper to catch up LOL. My father asked the Trooper "do you have kids"? Trooper said "yes", my father said "you would risk your life having children just to give me a speeding ticket"? That's not too smart my father told him.

I have an Arizona travel story as well. It includes Indian reservations and a cattle stampede

That one and the story of when my father died in Arizona and I had to retrieve his belongings. That was just about a life and death battle. It was survival in a way after an event occurred. I should say two events. I do have a couple of excellent titles in mind too for a movie. Problem is I don't trust Hollywood. They would steal my life event true story and give me nothing in compensation. Guaranteed that movie would be a blockbuster. Because you could not make this chit up what happened to me in those 13 days of Hell with that trip. It was really really phucked up. After that, I now know what the human mind is capable of thinking. Put it that way. Could not even grieve my father's death properly. As a side note, I am convinced my mother was killed/murdered - at the very least an early demise by euthanasia. Still trying to find a lawyer to take my case for no upfront costs. No luck yet.

Well that's true, but a mountain of a man!

Geez. Sounds like the makings of a good screenplay. Put in on paper and get your story told

That's one man's opinion.

I will check into that as you said. Maybe one day I will be able to restore my father's car to its former glory a 1964 Buick since I never saw my father much. He was around maybe 20 months in my whole life. Was hoping I would win the lottery by now, but it hasn't happened in the 24 years since he died. My mother is dead too and I am an only child. The only survivor left of my family and family name.
Have to honor my mother though, she raised me all by herself without any help from anyone. That is where the credit goes. I stayed honest and never did drugs. She had no help from my father who became destitute after losing all their money by opening a lounge in 1967 at a cost of $50,000 cash in those days. Put all the money into someone else's building - yes DUMB! Then after losing it all within 6 months and having a nervous breakdown, he stayed in it to try and recoup the $$$. Then he ended up owing $250,000 to the mafia and spent the rest of his life paying them off. So my mother had no support whatsoever and worked 6 days a week basically to raise me and keep us off welfare and out of homelessness. Yep, big money back then. He was a good father but made a truly stupid business decision. Well one day I will be rewarded, just maybe not on this side of eternity.

I'm SHOCKED to see this stock has a couple of buy recommendations from real sources. You just don't see that with a .38 stock.
This has been one of the few penny stocks that I've always thought MAY have a real product.....I dunno for sure, but I still say their financing in the past will keep them down.
I think their last reverse split was in 2017....but not sure what their other options are?
Nothing about this stock would give me hope, and yet.....I wouldn't rule anything out.
BTW, "not ruling anything out" is my highest rating I would give to a penny stock.

The stock is on the reverse split clock that expires, ironically, on the Ides of March. The company previewed that it would have preliminary results on the new trial in the first quarter. Expect to hear the result in the next few weeks. Worth a spec for a few Shekels at this 30- 40 cent level.

Geez! That reads like a very depressing Christmas card!
There is time to turn it around. Quit listening to the wrong people and start investing for slow and steady.
I post on my board what I'm buying and selling, its not a trade secret.
Sometimes I am wrong, but try to err to the conservative side. Better to lose opportunity than dollars.

Again you were right FD ! I was wrong and admit it all. I stopped all OTC stocks long ago. Even the NASDAQ stocks play the game of R/S then offerings, then rinse and repeat. Got burned there too. Just as in CRKN. Lost over $100 on it. Hope you are prospering in the market. Some of us just are not blessed I guess. I was always a loser anyways in life, so it is expected. Same as my friend Tim. We had similar lives and he is dead now. Both of our families lost their wealth. He was a good guy and as they say we finish last.

I've been telling anyone who will listen here for years. Legit company or not, they tied in with a toxic finance company whose only goal is to dump stock when possible.
This is the penny stock world. Why won't people learn?

Wow dropped even more. Glad I sold for an $800 loss at $1.79 long ago. This thing gets worse and worse. I am done with nasdaq and amex stocks. Just like OTC stocks. Can't buy those anyway since my broker does not allow non reporting stocks. Just buying NYSE stocks going forward, but must learn which ones to try first. All the other exchanges are CORRUPT. I have seen enough. Stocks run for no legit reason and others who make business go down the tubes. Everything is backwards in this world to logic.

And,... still no news on a start date,...

I don't see it in the near future. However it's possible for it to happen if they can't get the price above 1.00 before the deadline around March. We need some news on the trials progress to move the price higher. I've been here since 2009. Been through in one RS, really don't want to go through another. This company has done amazing well as a small biotech. I wouldn't still be here if I didn't believe they will succeed! Let's hope it's not to painful for shareholders before they bring this very effective drug to market. Got to keep the faith they will make it.

If you are a fan of the pump and dump, sometime between now and 3/15 you'll see a pump to near a $1. Then if history repeats, a fall to a new low.
This is just another small pharma who did a terrible death spiral finance deal in the past.

Do you see a RS in the near future? Thanks

So the price went below 1.00 on Sept 14th, a company is usually given up to 6 months to get the price back up above 1.00 for 10 consecutive days. That means we have until around March. We should get some kind of positive news before that, and the price goes above a dollar. Lets hope that happens before a reverse split.

This is BETTER than you expected?

Well - to be honest - share price is holding up better than I anticipated post dilution. Still stinks - but could be worse. Now they just have to get the confirmatory trial underway.
!
Happy New Year all!

That's odd. But makes sense it was free for a while because I posted. LOL

Oh I thought that Capitol Trades was legit ? You might be right. Here is what I saw:


Michael McCaul
RepublicanHouseTX
EQV VENTURES ACQN CORP -REDH
EQV:US
18 Dec
2024
12 Nov
2024
days
33
Spouse
buy
100K–250K
$9.92

https://www.capitoltrades.com/trades/20003780146

My board has been premium for the last few years. I believe premium boards were open to all last week as a gift. I need to see if they will change it back to free.
Again, show me any proof that Congressmen are buying EQV. This sounds like hoooey to me. If I thought it was in any way legit, I'd also put $100k into it.....but I won't. Sounds like internet hype to me. Don't believe everything ya read.
And Happy New Year to you as well. Lets invest smarter for 2025. It ain't gonna be as easy this year.

Thank you FD ! Happy New Year to you and your family ! Will talk to you tomorrow after 4pm. For some reason your board changed to Premium ??? LOL Won't let me post now. Very strange. And YES I bought that EQV stock. To my understanding it is a shell. I only bought 10 shares because people in Congress loaded up buying $100K+ worth. Out of my league, but I spend what I can risk and afford. Peanuts to many LOL.

A nice move??? It's far below last week's low.
If you look at the volume days, other than 12/19, all the volume days were selling.
The largest day of trading was 12/30, which looks like a big tax loss selling day. Would large positions be selling with good news on the way?

Looks like a nice move off the low.

Your statement about the lack of volume is misleading. In fact, the daily volume is also at multiyear highs . Looks like accumulation to me by people expecting good news in th4e near future.

Interesting phraseology by you.....

Your belief that phase test results are revealed before they are announced is erroneous.

Guess you'd have to define "revealed".
I would say, in ALL companies, insiders know info before common shareholders. News leaks via friends and family. Volume rises.
Chart reading is an art form, that typically posters on IHUB do poorly.

No offense taken. I've owned this quite a while back so its still on my follow list.
However, I am a researcher of penny stock posters. I try to expose the distrustful ones and teach the naive ones.
Why would anyone be opposed to varied viewpoints?
I exposed this stock some years back for having made a terrible death spiral finance deal with a known fraudulent company.

No offense, I am curious why you post on this board when you admittedly own no shares.
I am not here to pump the stock which now trades at multiyear lows. I believe the technology will prove to be a lifesaver and a great investment for those who stayed the course.
Your belief that phase test results are revealed before they are announced is erroneous.

No offense, but your sentiment is one that has been shared here since I made my first post on this board.
Considering the lack of volume, and the fact this stock has done nothing but sink for years, I would say, this is DEFINITELY NOT the time to be buying this stock. Should this trend change, there will be more than enough time to buy in.
The only value now, is to anyone looking to pump then dump the stock. On your own personal level, I am curious.....would you feel at all bad making money on this stock if it was totally due to getting in early on a pump and dump scheme? Knowing full well you'd be sticking your shares to someone else presumably on this very website?

The lack of success here can be attributable to the failure to date of Multikline as a cancer cure or mitigator of head and neck cancer not the CEO. That being said, this can still be a huge winner, especially given the cheap entry point now, should the ongoing tests, with preliminary results expected in the current quarter, prove successful. If you are lucky, this can be your personal ATM.

Indeed

The reason the company filed for an extension of the 10K is that the deal which just occurred does not close until tomorrow and must be included in the 10K.

Geerts hitting his personal ATM
Hopefully we will get back over $1 before this huckster calls for a reverse split. Been here over 15+ years should have bailed when it stood for months at $25 but had faithin Multikine, should have realized Geert was taking too long with telling full results. Geert is a huckster in it only for himself and what he can make with it.

Sometime in the first quarter there should be some preliminary results on the CRO Confirmatory trial study. If positive, the stock should trade above $1 making the need to reverse split the stock moot. I'm adding here.